Trevi Therapeutics, Inc., a New Haven, CT-based late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus conditions, closed a $15m senior secured term loan agreement.
The facility was provided by Solar Capital as collateral agent and lender and Square 1 Bank as lender.
The company intends to use the funds to complete the funding for its ongoing clinical trials of Nalbuphine ER in uremic pruritus and prurigo nodularis.
Founded in 2011 and led by Jennifer Good, President and CEO, Trevi Therapeutics focuses on developing Nalbuphine ER for chronic pruritus (itch) and is pursuing two conditions for clinical development:
uremic pruritus, a persistent and debilitating itch in patients on dialysis that has been associated with increased mortality, and prurigo nodularis, a chronic dermatologic condition characterized by severely pruritic nodules on the skin that are independent of underlying etiology.